Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ascletis Pharma, Inc. (HK:1672)
HKEX:1672
Holding HK:1672?
Track your performance easily
1672 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$0.76 - HK$1.97
Previous CloseHK$1.84
Volume3.82M
Average Volume (3M)2.42M
Market Cap
HK$1.81B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Mar 24, 2025EPS Estimate
-HK$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares OutstandingN/A
10 Day Avg. Volume1,958,700
30 Day Avg. Volume2,421,357
Standard Deviation0.18
R-Squared0.13
Alpha0.00256
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ascletis Pharma, Inc. News
PremiumCompany Announcements
Ascletis Pharma Advances in Phase III Acne Treatment Trial
PremiumCompany Announcements
Ascletis Pharma Unveils Promising ASC47 Weight Loss Results
PremiumCompany Announcements
Ascletis Pharma Contests US Importation Ban
PremiumCompany Announcements
Ascletis Pharma’s Partner Gains FDA Breakthrough Status
PremiumCompany Announcements
Ascletis Pharma Revises Proceeds Allocation StrategyPremiumCompany Announcements
Ascletis Pharma Debuts Dual-Method Obesity Drug Trials
PremiumCompany Announcements
Ascletis Pharma Reports Increased Loss and R&D Progress
PremiumCompany Announcements
Ascletis Pharma Forecasts Substantial Mid-Year LossOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.20% Mutual Funds
― Other Institutional Investors
99.78% Public Companies and
Individual Investors
1672 FAQ
What was Ascletis Pharma, Inc.’s price range in the past 12 months?
Ascletis Pharma, Inc. lowest stock price was HK$0.76 and its highest was HK$1.97 in the past 12 months.
What is Ascletis Pharma, Inc.’s market cap?
Currently, no data Available
When is Ascletis Pharma, Inc.’s upcoming earnings report date?
Ascletis Pharma, Inc.’s upcoming earnings report date is Mar 24, 2025 which is in 122 days.
How were Ascletis Pharma, Inc.’s earnings last quarter?
Ascletis Pharma, Inc. released its earnings results on Aug 30, 2024. The company reported -HK$0.141 earnings per share for the quarter, missing the consensus estimate of -HK$0.13 by -HK$0.011.
Is Ascletis Pharma, Inc. overvalued?
According to Wall Street analysts Ascletis Pharma, Inc.’s price is currently Overvalued.
Does Ascletis Pharma, Inc. pay dividends?
Ascletis Pharma, Inc. does not currently pay dividends.
What is Ascletis Pharma, Inc.’s EPS estimate?
Ascletis Pharma, Inc.’s EPS estimate is -HK$0.16.
How many shares outstanding does Ascletis Pharma, Inc. have?
Ascletis Pharma, Inc. has 984,684,000 shares outstanding.
What happened to Ascletis Pharma, Inc.’s price movement after its last earnings report?
Ascletis Pharma, Inc. reported an EPS of -HK$0.141 in its last earnings report, missing expectations of -HK$0.13. Following the earnings report the stock price went up 2.41%.
Which hedge fund is a major shareholder of Ascletis Pharma, Inc.?
Currently, no hedge funds are holding shares in HK:1672
---
Ascletis Pharma, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.66%
12-Months-Change
Fundamentals
Return on Equity
-10.94%
Trailing 12-Months
Asset Growth
-14.77%
Trailing 12-Months
Company Description
Ascletis Pharma, Inc.
Ascletis Pharma Inc is a research and development driven biotechnology company which provides medical solutions in the field of antiviral, cancer, and fatty liver diseases. The products in the pipeline include HCV, HBV, ASC09, and ASC06. It currently has five anti-viral drug discovery and development programs, including two HCV drug candidates near commercial-stage and one HIV drug candidate that has completed a phase IIa clinical trial. Geographically, it operates in Mainland China and other countries.
---
1672 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Viva Biotech Holdings
―
Akeso, Inc.
―
Million Hope Industries Holdings Ltd.
―
Billion Industrial Holdings Ltd.
―
Best Analysts Covering 1672
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
-6.83%
reiterated a buy rating 7 months ago
Copying Chris Lui's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of -6.83% per trade.
---